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A mouse model of spontaneous latent tuberculosis infection (LTBI) that mimics LTBI
in humans is valuable for drug/vaccine development and the study of tuberculosis.
However, most LTBI mouse models require interventions, and a spontaneous LTBI
mouse model with a low bacterial load is difficult to establish. In this study, mice were
IV-inoculated with 100 CFU Mycobacterium tuberculosis H37Rv, and a persistent LTBI
was established with low bacterial loads (0.5∼1.5log10 CFU in the lung; <4log10 CFU in
the spleen). Histopathological changes in the lung and spleen weremild during the first 20
weeks post-inoculation. The model was used to demonstrate the comparative effects of
prophylactic and therapeutic administration of Ganoderma lucidum extract (spores and
spores lipid) in preventing H37Rv replication in both lung and spleen. H37Rv was inhibited
with prophylactic use of G. lucidum extract relative to that of the untreated control and
therapy groups, and observed in the spleen and lung as early as post-inoculation week
3 and week 5 respectively. H37Rv infection in the therapy group was comparable to
that of the untreated control mice. No significant mitigation of pathological changes was
observed in either the prophylactic or therapeutic group. Our results suggest that this
new LTBI mouse model is an efficient tool of testing anti-tuberculosis drug, the use of
G. lucidum extract prior toM. tuberculosis infectionmay protect the host against bacterial
replication to some extent.
Keywords: mouse model, spontaneous latent tuberculosis infection, Ganoderma lucidum extract, prophylactic
use, inhibited Mycobacterium tuberculosis replication
INTRODUCTION
Approximately one third of the world’s population is infected withMycobacterium tuberculosis, and
about 90% of these infections are latent. A better understanding of mechanisms leading to latency
is required to help prevent, control, treat, and eliminate tuberculosis infection and disease.
Similar to other latent infections, M. tuberculosis in latent tuberculosis infection
(LTBI) replicates at low levels in the infected organs, and therefore histopathology results
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are absent or mild. There are several established LTBI animal
models, including mice (Scanga et al., 1999), guinea pigs
(Kashino et al., 2008), rats (Singhal et al., 2011), rabbits (Manabe
et al., 2008), and nonhuman primates (Lin et al., 2009a). These
models have been used to identify host factors that contribute
to the establishment and maintenance ofM. tuberculosis latency,
and reactivation of replication. One of the most recognized
LTBI mouse models is the Cornell model, which is created by
inhibiting M. tuberculosis replication with intervening factors
(Lenaerts et al., 2004;Woolhiser et al., 2007). However, there is no
currently available mouse model of spontaneously paucibacillary
tuberculosis.
The three primary parameters used for evaluating vaccine
or drug candidate against tuberculosis are the bacterial load,
pathological change in the lung, and the tuberculosis relapse
rate in the latter phase of LTBI. With the current LTBI mouse
model, the period of latency is relatively long, and to complete
the evaluation can require 3–7 months (Ziv et al., 2001; Ha
et al., 2003; Zhang et al., 2011). Thus, the current models
are inefficient and costly, and slow the development of new
tuberculosis vaccines and drug treatments.
A previous study showed that a proteoglycan extracted from
the fruiting bodies of the bracket (polypore) fungus G. lucidum
could be a preventative of diabetic complications (Pan et al.,
2013). Furthermore, triterpenes of G. lucidum were shown to
exert anti-lung cancer activity in vitro and in vivo, and such anti-
cancer activity was mediated by enhancing immunomodulation
and induction of cellular apoptosis (Feng et al., 2013). Also of
note is that polysaccharides purified from the submerged culture
of G. formosanum can activate macrophages and protect mice
against Listeria monocytogenes infection (Wang et al., 2011).
G. lucidum can also regulate natural killer cells (Chien et al.,
2004), macrophages (Yeh et al., 2010), T cells (Lai et al., 2010;
Yoshida et al., 2012), and dendritic cells (Meng et al., 2011), all of
which are actively involved in the innate and adaptive immune
responses to M. tuberculosis infection. Thus, we wondered
whether G. lucidum could protect the host from M. tuberculosis
infection.
To test our hypothesis, in the present study we established
a novel mouse model of spontaneous LTBI, with a shorter
latency period and lower bacterial load than previous models.
We then evaluated the protective effects against M. tuberculosis
infection in this new model exerted by the Takayama G. Lucidum
(MeiShanTang, Hong Kong), which is rich in triterpenes, and is
proven effective in treating simian acquired immune deficiency
syndrome via the immune system (Lu et al., 2011).
MATERIALS AND METHODS
Ethics Statement
The Institute of Animal Use and Care Committee of the Institute
of Laboratory Animal Science, Peking Union Medical College
approved all protocols and procedures that involved animals
(ILAS-PC-2013-015). All mice were housed in plastic cages
(6/cage) with free access to drinking water and a pellet diet, under
controlled humidity (50 ± 10%), light (12/12 h light/dark cycle),
and temperature (23 ± 2◦C) conditions in an Animal Biosafety
Level 3 (ABSL-3) facility. Prior to procedures performed at each
time-point, mice were fasted overnight and then given anesthesia.
Establishment of the LTBI Mouse Model
Bacterial Strain
The M. tuberculosis strain H37Rv was first cultured in
Löwenstein-Jensen plates (L-J plates) for 3 weeks, to mid-
log phase. Then the bacteria were harvested using a sterilized
L-shaped glass rod and resuspended in 0.9% NaCl in a glass
grinder. The suspension was filtered through a 5µm membrane
and the bacterial density adjusted to ∼1 × 107 colony-forming
units (CFU)/mL. An aliquot of bacilli were then plated on an L-J
plate for CFU enumeration.
Mice
Specific-pathogen free female C57BL/6 mice (6–8 weeks old,
n = 450) were obtained from Vital River Laboratory Animal
Technology (China).Mice weremaintained in anABSL-3 specific
pathogen-free facility and allowed food and water ad libitum.
Inoculation of Mice with M. tuberculosis
The mice were randomly and equally apportioned to an infection
or a blank control group, 150 mice for each experiment, 75 mice
for infection and blank control group each, the experiment would
be repeated 3 times with 1 week interval. Mice in the infection
group were inoculated through the tail vein with 0.1mL of H37Rv
(1 × 103 CFU/ mL), that was 100CFU for each mouse, and
control mice were similarly injected with 0.1mL 0.9% NaCl. All
procedures were performed in a biosafety cabinet located in the
ABSL-3 facility.
Analysis of Pathologic Changes
Six mice were sacrificed at each time-point (weeks 1, 3, 5, 8,
12, 16, 20, and 24), for the first experiment, the rest mice were
sacrificed at week 34, 38, 44 and 52(see Supplementary Image
2), six for each time-point, and for the latter two experiments,
the rest mice were sacrificed at 52th week. The lung, spleen,
and liver were removed from each animal; gross lesions were
examined and described. The necropsy tissues were fixed and
paraffin-embedded. The sections were cut and stained with
hematoxylin and eosin, and reviewed by a veterinary pathologist.
Semi-quantitative scores were assigned to reflect the lesion size
and extent of inflammation of the entire lung field: +, 25%; ++,
50%;+++, 75%.
Quantitative Culture of Lung and Spleen
Homogenates
The lung and spleen tissues taken at necropsy were washed in 4%
H2SO4 and homogenized in 0.9% NaCl. Serial dilutions of the
homogenous lung fluid were used to inoculate the L-J medium
culture in tubes, which were incubated at 37◦C and 5% CO2. The
bacterial counts in the tubes were read after 21 days. At each time-
point, the mean of the bacterial loads in each organ type of 6 mice
were calculated.
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Evaluation of the Protective Effect of
G. Lucidum in the LTBI Mouse Model
Study Design
The mice were divided into an LTBI mouse model control group,
a G. lucidum prophylaxis group, and a therapy group. Mice
in the control group were inoculated with M. tuberculosis as
described above, but were fed normally and not given G. lucidum
extract. The prophylaxis group received daily doses ofG. lucidum
mushroom extract (described below) beginning 1 month before
M. tuberculosis inoculation and until 16 weeks after inoculation.
In the therapy group, mice were given daily doses of G. lucidum
mushroom extract beginning at the time of inoculation and
lasting 16 weeks.
Preparation of G. lucidum Extract-Containing Food
Takaya Shell-broken Ganoderma Lucid Spores and Spores Lipid,
which were rich in terpene carbon dioxide extraction from
included species of G. lucidum (MeiShanTang, Hong Kong)
were mixed with the mouse feed powder and water, and then
the mixture was manually formulated into ∼15-cm-long feed
strips with diameter of 1.5 cm. The strips were dried in the
37◦C oven for 48 h. Each mouse received daily 15mg of G.
lucidum spores and 15mg spore lipids in 4 g of feed (Lu et al.,
2011).
Mouse Trails
In the prophylaxis group, the feeding duration of G. lucidum
was 20 weeks, starting 1 month before M. tuberculosis
inoculation and continuing to the 16th week post-inoculation.
In the therapy group, dietary G. lucidum (including spores
and spore lipids) was administrated for 16 weeks, from
the inoculation of M. tuberculosis to the 16th week post-
inoculation. The effect of G. lucidum on M. tuberculosis
infection in mice was evaluated according to the bacterial
load in the lung and spleen, and the pathological changes
in the lung, spleen, and liver at 3, 5, 8, and 16 weeks
post-inoculation.
Fluorescence-Activated Cell Sorting (FACS) Analysis
of Immune Cells
Dendritic, natural killer, CD4+/CD8+ T cells, and regulatory
T (Treg) cells in the peripheral blood and lung were stained
with specific antibody (all from eBioscience) for 30min at 4◦C.
The following mouse antibodies were used: CD11b-fluorescein
isothiocyanate (FITC) and CD4-FITC; I-AB-phycoerythrin (PE),
CD86-PE, CD8-PE, CD49b-PE, and FOXP3-PE; CD80-peridinin
chlorophyll protein complex (PERCP) and CD3-PERCP; and
CD11c-allophycocyanin (APC), perforin-APC, and CD25-APC.
The stained cells were analyzed by FACS.
Statistical Analyses
Quantitative data are expressed as the mean ± standard error
of the mean (SEM), and analyzed using a two-tailed Student’s
t-test and ANOVA. P < 0.05 was considered statistically
significant.
RESULTS
Bacterial Loads in the Lung and Spleen of
the LTBI Mouse
The bacterial loads of lung and spleen in the infection and blank
control groups at 1, 3, 5, 8, 12, 16, 20, and 24 weeks after
inoculation withM. tuberculosis was determined (Figures 1A,B).
NoM. tuberculosis was detected in the blank control mice at any
time-point. In the lungs of the infection group, themean bacterial
load was ∼1.5log10 CFU at 3rd week, at the lowest level found
(∼0.5 log10 CFU) at 8th week, fluctuated from indeterminably
low to ∼2log10 CFU at 8–20th week, and was ∼2.5 log10 CFU
at week 24 (Figure 1A). In the spleens of the mice in the
infection group, the mean bacterial load at 3rd week was 4.5log10
CFU, then 2.1log10 CFU at 8th week, and was subsequently
progressively higher at each time-point, to >4 log10 CFU at week
24 (Figure 1B). Compared with blank control, both the bacteria
loads of spleen and lung in infected group had significant statistic
difference (∗∗∗P < 0.001).
There were no observed gross pathological changes
throughout the infection course in any group, but
histopathological changes were observed under the light
microscope. In the lung at week 3, mild infiltration with
inflammatory cells in the peripheral vascular was observed
in the lung. At week 5, a granuloma-like structure in the
lung was observed, and scored as a severe lesion (+++).
However, at week 8, the histopathologic lesion was not seen,
and only a few inflammatory cells infiltrated vessels. Infiltration
of inflammatory cells in the lung was greater at week 16
(Figure 2).
In the spleen at 3rd week, several small granulomas (diameter,
5–50µm) were detected in the white pulp. At week 5, the
granulomas in the white pulp of the spleen were of diameters
20–150µm, but at week 8 granuloma sizes were 5–20µm. At
week 20, several granuloma-like lesions of size 10–50µm were
observed in the spleen white pulp (Figure 2).
At week 3–16, granuloma-like lesions were occasionally
observed in the hepatic lobule. The size of irregularly shaped
granuloma-like lesions at week 3 was∼50× 350µm, and smaller
granuloma-like lesions (20–50µm) were present from weeks 5 to
20 (Figure 2).
Bacterial Loads in the Lung and Spleen of
G. lucidum Extract-Treated Mice
The condition of mice inoculated with 100 CFU M. tuberculosis
resembled LTBI during the first 20 weeks post-inoculation.
Therefore, to evaluate the effect of the G. lucidum extract, we
determined the bacterial loads of the control and model mice at
time-points up to 16 weeks post-inoculation.
In the prophylaxis group, in the lung the bacterial load was
essentially none up through week 8, but was (0.42 ± 0.34)
log10 CFU at week 16 (Figure 3A). In the therapy group, the
M. tuberculosis level in the lung remained essentially undetectable
through the first 3 weeks, but was (1.39± 0.77) log10 CFU at week
5, (0.42 ± 0.42) log10 CFU at week 8, and again undetectable
at week 16. In the spleens of the prophylaxis group, the mean
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FIGURE 1 | The replication kinetics of M. tuberculosis in the lung and spleen. Bacterial loads (log10CFU) in (A) the lung and (B) spleen were counted on the
L-J medium from week 1 to week 24. Six mice for each time-point in each group. One of three similar experiments is shown. The SEMs are plotted as error bars.
T-test and ANOVA analysis, ***P < 0.001.
M. tuberculosis levels were (1.69 ± 0.71) log10 CFU at week 3,
(1.12 ± 0.77) log10 CFU at week 5, (3.48 ± 0.11) log10 CFU at
week 8, and (2.41± 0.41) log10 CFU at week 16. In the spleens of
the therapy group, the bacterial loads were similar to that of the
control group: a peak value at (4.33 ± 0.75) log10 CFU at week
3, (3.56 ± 0.05) log10 CFU at week 5, (3.22 ± 0.17) log10 CFU at
week 8, and (3.04 ± 0.17) log10 CFU at week 16(Figure 3B). As
for spleen bacteria loads, the prophylaxis group showed statistical
differences at both week 3 and 5, compared with both blank
control and therapy group (W3, P < 0.05; W5, P < 0.01),
and only with control group at week 8(P < 0.05); but for
lung bacteria loads, the prophylaxis group revealed significant
statistic difference only at week 5, compared with therapy group
(Figures 3A,B).
Histopathologic Changes in
G. lucidum-Treated Mice
There were no macroscopic changes in the lungs, spleens,
or livers in any of the groups, and no visible differences in
the microscopic histology of the spleens or livers. However,
histological differences in the lung were detected.
In the LTBI model control (untreated) group, inflammatory
lesions were aggravated at week 5 compared with week 3,
but were not seen from week 8 to 16. Similar to the
control group, in the prophylaxis and therapy group small
lesions peaked at week 5, and then were absent at week
8–16. At week 5, inflammation in the prophylaxis group was
milder than inflammation in the control group (Figure 4A).
Compared with the control group, mice in the G. lucidum
prophylaxis group had lower pathology scores during the
infection course, but the difference was not significant (P > 0.05;
Figure 4B).
Percentages of Dendritic Cell, Natural
Killer Cell, and Treg Cell, and the Ratios of
CD4+/CD8+T cell in Blood
The number of dendritic cell, natural killer cell, Treg cell,
and the ratio of CD4+/CD8+ T cell in the peripheral blood
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FIGURE 2 | Histopathological changes over time (100×). (A0–A20) Lung histology at weeks 0, 3, 5, 8, and 20, respectively. (B0–B20) Spleen histopathology at
weeks 0, 3, 5, 8, and 20. (C0–C20) Liver histopathology at weeks 0, 3, 5, 8, and 20. Arrow indicates granulomas-like lesion.
were analyzed by FACS (Figure 5). In the prophylaxis group,
the percentages of dendritic cell were 14.8 ± 5.04% at week
3, 6.56 ± 1.93% at week 5, 1.22 ± 0.10% at week 8,
and 7.64 ± 2.69% at week 16. In the therapy and control
group, the percentages of dendritic cells were similar to
that of the prophylaxis group, progressively increasing over
time from 9.24 ± 1.55% at week 3 to 18.48 ± 2.00%
at week 16.
The percentages of natural killer cell in the prophylaxis group
was 2.70 ± 0.68% at week 3, 9.82 ± 1.48% at week 5, 15.76 ±
2.63% at week 8, and 7.15 ± 1.20% at week 16. The percentages
of natural killer cell in the control and therapy group were
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FIGURE 3 | Differences in bacterial loads between the control group and G. lucidum-treated (therapy and prophylaxis) mice. Bacterial loads (log10 CFU)
in the (A) lung and (B) spleen were counted on the L-J medium from week 0 to week 16. One of three similar experiments is shown. The SEMs are plotted as error
bars. ANOVA analysis, *P < 0.05, **P < 0.01.
comparable: ∼2, ∼10, ∼5, and ∼7% at weeks 3, 5, 8, and 16,
respectively.
The ratios of CD4+/CD8+T cells in all three groups were
similar and stable at∼1.8 throughout the infection period, except
for the prophylaxis group, in which a mean ratio of ∼4.2 was
observed at week 8.
The percentages of Treg cells in the prophylaxis group were
0.86 ± 0.05% at week 3, 0.49 ± 0.08% at week 5, 1.63 ± 0.08% at
week 8, and 0.76 ± 0.12% at week 16. In the control and therapy
group, the percentages of Treg cells were similar (∼1%) at week
5, and progressively and similarly decreased from week 5 to16
(Figure 5).
DISCUSSION
We present here a novel mouse model of spontaneous LTBI,
which closely resembles human LTBI. The model was generated
through experimental inoculation of M. tuberculosis without
resorting to other means such as anti-tuberculosis drugs
treatment or Mycobacterium bovis Bacillus Calmette-Guerin
vaccination. A useful application of this model is to evaluate
anti-tuberculosis drugs or vaccines during the early latency
phase, which would be more efficient than the previous models
(Ziv et al., 2001; Ha et al., 2003; Zhang et al., 2011). In
the present study, we demonstrated the efficiency of the new
mouse LTBI model by testing the effect of G. lucidum extract
on M. tuberculosis infection, by inhibiting M. tuberculosis
replication.
To initiate the LTBI model, C57BL/6 mice were IV-injected
with 100 CFU M. tuberculosis inoculum. M. Tuberculosis
initially replicated in the lung and spleen, with bacterial
loads rising until week 3, after which infection entered into
a latent phase with M. tuberculosis levels declining from
week 3 and stabilizing at a lower level till week 20. In
accord with the bacterial load findings, pathological changes
were detected at week 3, which became prominent at week
5, and then subsided to only mild perivascular inflammation
from week 8 to 20. M. tuberculosis replication shifted
from relatively active to dormant, resulting in lower bacterial
loads and mild pathological changes in both the lung and
spleen from weeks 8 to 20 post-inoculation. Thus, the period
within 8 weeks would be regarded as “pre-latency phase,”
and the period from week 8 to week 20 comprised the
real latency phase of M. tuberculosis infection in this model
(Figures 2, 3). The bacteria load curves of spleen and lung
were similar to others study, but with lower value and
shorter latency period, which would be more efficient in drug
evaluation.
Treatment of mice with G. lucidum extract beginning
1 month before inoculation with M. tuberculosis (the
prophylaxis group) inhibited replication of the bacterium
in the lung and spleen during the first 8 weeks post-
inoculation, relative to untreated control mice and mice
treated from the time of inoculation (the therapy group).
This inhibition was especially evident in the spleen 5 weeks
after inoculation. No significant inhibition of M. tuberculosis
replication was observed in the therapy group, suggesting
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FIGURE 4 | Pathology of the lung. (A) Histopathology of the lungs at weeks 3, 5, 8, and 16 weeks of representative mice in the (A3–A16) control, (B3–B16)
prophylaxis, and (C3–C16) therapy groups (200×). (B) Pathological lesion scores in the lung of mice in the control, therapy and prophylaxis groups at weeks 3, 5, 8,
and 16. SEMs are plotted (P > 0.05).
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FIGURE 5 | Percentages of dendritic cells (DC), natural killer (NK) cells, and Treg cells, and the ratios of CD4+/CD8+T cells in the blood. The results are
expressed as mean ± SEM, plotted using GraphPad Prism version 4.01 (GraphPad, San Diego, CA).
that early use of G. lucidum extract is probably required
for exerting anti- tuberculosis activity in this mouse model
(Figure 4).
The changes of immune cell percentages in the peripheral
blood did not correlate with the bacterial loads ofM. tuberculosis
or pathological changes observed in the lung and spleen.
However, responses of the peripheral blood and lung to
inoculation were opposed, with regard to percentages of dendritic
cells. At post-inoculation week 3, the number of peripheral
dendritic cells in prophylaxis group was higher than that in
the control group, but at week 5 was lower than the control
group, while the number of dendritic cells in the prophylaxis
group lung was higher at week 5 than week 3 (Supplementary
Data), and higher than the control group. These changes
suggest that dendritic cells may have transferred from the
peripheral blood to the lung from week 3 to week 5, and the
accumulation of dendritic cells in the lung might participate
in and augment the repression of M. tuberculosis replication,
inferred from the immune effect of G. lucidum on dendritic cells
in previous research (Figure 5) (Lin et al., 2009b; Meng et al.,
2011).
However, the immune mechanism ofG. lucidum extract could
not be discerned, and nor if the effective constituent was terpenes,
which should be investigated in a further study.
In conclusion, we established a mouse model resembling
human M. tuberculosis LTBI. The early acute phase of infection
(from inoculation to week 8) and the relatively short latency
period makes this model useful for evaluating anti-tuberculosis
drugs. We utilized the model to investigate the effect of G.
lucidum extract on M. tuberculosis infection. We found that
administration of Takaya G. lucidum extract prior to inoculation
of M. tuberculosis was associated with lower levels of bacterial
replication in this model.
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